Document Detail


Prostacyclin therapy for pulmonary arterial hypertension: new directions.
MedLine Citation:
PMID:  16121316     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Pulmonary arterial hypertension (PAH) is characterized by vasoconstriction and smooth muscle cell proliferation of the pulmonary arterioles, as well as in situ thrombosis of the small pulmonary arteries. Prostacyclin is involved in PAH vascular remodeling. It is unclear if decreased prostacyclin in the lungs is a cause or a consequence of PAH, but the relative lack of prostacyclin and its positive effects on the pulmonary vascular bed support the theory that long-term prostacyclin replacement is effective. Current therapies based on evidence-based medicine include epoprostenol, treprostinil, iloprost, and beraprost, each with limitations based on the drugs' inherent properties and administration route. Treatment of PAH by inhibiting multiple pathways concurrently may produce additive benefit. Because prostacyclin therapy is not curative and does not normalize pulmonary hemodynamics in the majority of cases, combining a prostacyclin with other PAH agents may be a promising approach.
Authors:
Mardi Gomberg-Maitland; Ioana R Preston
Related Documents :
2011406 - Disappearance of molsidomine effects on pulmonary circulation of patients with chronic ...
1244236 - Morphological development of the pulmonary vascular bed in fetal lambs.
17338936 - Portopulmonary hypertension.
2689066 - Pulmonary and pleural complications of cardiac disease.
8746836 - Proximal migration of vena caval filters: report of two cases with operative retrieval.
6662646 - Aorto-intestinal fistula after reconstructive arterial surgery.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Seminars in respiratory and critical care medicine     Volume:  26     ISSN:  1069-3424     ISO Abbreviation:  Semin Respir Crit Care Med     Publication Date:  2005 Aug 
Date Detail:
Created Date:  2005-08-25     Completed Date:  2006-01-12     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9431858     Medline TA:  Semin Respir Crit Care Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  394-401     Citation Subset:  IM    
Affiliation:
Division of Cardiology, University of Chicago Hospitals, IL 60637, USA. mgomberg@medicine.bsd.uchicago.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antihypertensive Agents / therapeutic use*
Clinical Trials as Topic
Drug Therapy, Combination
Epoprostenol / analogs & derivatives,  therapeutic use*
Humans
Hypertension, Pulmonary / drug therapy*
Iloprost / therapeutic use
Vasodilator Agents / therapeutic use
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Vasodilator Agents; 0/treprostinil; 35121-78-9/Epoprostenol; 78919-13-8/Iloprost; 88430-50-6/beraprost

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Brain natriuretic peptide: diagnostic and therapeutic implications in pulmonary arterial hypertensio...
Next Document:  Endothelin antagonism in pulmonary arterial hypertension.